These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9414415

  • 1. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
    Jayaram HN, O'Connor A, Grant MR, Yang H, Grieco PA, Cooney DA.
    J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
    [Abstract] [Full Text] [Related]

  • 2. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN, Zhen W, Gharehbaghi K.
    Cancer Res; 1993 May 15; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase.
    Gharehbaghi K, Paull KD, Kelley JA, Barchi JJ, Marquez VE, Cooney DA, Monks A, Scudiero D, Krohn K, Jayaram HN.
    Int J Cancer; 1994 Mar 15; 56(6):892-9. PubMed ID: 7907081
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells.
    Grusch M, Rosenberger G, Fuhrmann G, Braun K, Titscher B, Szekeres T, Fritzer-Skekeres M, Oberhuber G, Krohn K, Hengstschlaeger M, Krupitza G, Jayaram HN.
    Cell Death Differ; 1999 Aug 15; 6(8):736-44. PubMed ID: 10467347
    [Abstract] [Full Text] [Related]

  • 11. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G, Weber G.
    Anticancer Res; 1996 Aug 15; 16(6A):3341-7. PubMed ID: 9042309
    [Abstract] [Full Text] [Related]

  • 12. Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside.
    Jäger W, Salamon A, Szekeres T.
    Curr Med Chem; 2002 Apr 15; 9(7):781-6. PubMed ID: 11966442
    [Abstract] [Full Text] [Related]

  • 13. Staurosporine enhanced benzamide riboside-induced apoptosis in human multidrug-resistant promyelocytic leukemia cells (HL-60/VCR) in vitro.
    Hunáková L, Duraj J, Romanová D, Novotný L, Sedlák J, Kelley MR, Szekeres T, Jayaram HN, Chorváth B.
    Neoplasma; 1998 Apr 15; 45(4):204-9. PubMed ID: 9890662
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
    Jayaram HN, Cooney DA, Grusch M, Krupitza G.
    Curr Med Chem; 1999 Jul 15; 6(7):561-74. PubMed ID: 10390601
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.
    Peñuelas S, Noé V, Morales R, Ciudad CJ.
    Med Sci Monit; 2005 Jan 15; 11(1):BR6-12. PubMed ID: 15614187
    [Abstract] [Full Text] [Related]

  • 18. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
    Wright DG, Boosalis MS, Waraska K, Oshry LJ, Weintraub LR, Vosburgh E.
    Anticancer Res; 1996 Jan 15; 16(6A):3349-51. PubMed ID: 9042310
    [Abstract] [Full Text] [Related]

  • 19. Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase.
    Yalowitz JA, Jayaram HN.
    Curr Med Chem; 2002 Apr 15; 9(7):749-58. PubMed ID: 11966438
    [Abstract] [Full Text] [Related]

  • 20. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.